We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In this episode of ETF Spotlight, I speak with Tim Seymour, founder & CIO of Seymour Asset Management and co-host of CNBC's Fast Money, and Christian Magoon, founder & CEO of Amplify ETFs.
We discuss cannabis investing and the Amplify Seymour Cannabis ETF (CNBS - Free Report) , which is actively managed by Tim.
We start with the investment case for cannabis--why investors should consider marijuana stocks and ETFs. Per Amplify, global legal cannabis sales have risen approximately 30% per year recently, with 2019 sales expected to grow 39% from 2018.
Tim is an early stage cannabis investor and also serves as a board member for several private cannabis companies. What drew him to the cannabis industry?
Recreational marijuana use is now legal in 11 states and Washington D.C. and medical marijuana use is legal in 33 states, but it remains illegal at the federal level. We discuss the current regulatory landscape, rising support for legalizing cannabis and recent legislative developments.
CNBS invests in marijuana companies that derive 50% or more of their revenue from the cannabis and hemp ecosystem. Its top holdings include Canopy Growth (CGC - Free Report) Aurora Cannabis (ACB - Free Report) , GW Pharmaceuticals MediPharm Labs, Organigram Holdings (OGI - Free Report) Village Farms International (VFF - Free Report) and Canaccord Genuity.
Tim talks about some of his favorite cannabis stocks.
There are four more pot ETFs available to investors now--the ETFMG Alternative Harvest ETF (MJ - Free Report) , the AdvisorShares Pure Cannabis ETF (YOLO - Free Report) , The Cannabis ETF and the Cambria Cannabis ETF (TOKE - Free Report) . How is CNBS different from other pot ETFs?
Are there any pot stocks investors should stay away from? CannTrust Holdings has lost more than 50% of its value since it disclosed a serious regulatory breach on July 8. What else do investors need to know?
Amplify has a number of ETFs focused on disruptive themes, like the Amplify Online Retail ETF (IBUY - Free Report) . We talk about the role of thematic ETFs in investors’ portfolios.
Please visit AmplifyETF.com to learn more about CNBS and other Amplify ETFs.
Make sure to be on the lookout for the next edition of ETF Spotlight! If you have any comments or questions, please email podcast@zacks.com.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
In this episode of ETF Spotlight, I speak with Tim Seymour, founder & CIO of Seymour Asset Management and co-host of CNBC's Fast Money, and Christian Magoon, founder & CEO of Amplify ETFs.
We discuss cannabis investing and the Amplify Seymour Cannabis ETF (CNBS - Free Report) , which is actively managed by Tim.
We start with the investment case for cannabis--why investors should consider marijuana stocks and ETFs. Per Amplify, global legal cannabis sales have risen approximately 30% per year recently, with 2019 sales expected to grow 39% from 2018.
Tim is an early stage cannabis investor and also serves as a board member for several private cannabis companies. What drew him to the cannabis industry?
Recreational marijuana use is now legal in 11 states and Washington D.C. and medical marijuana use is legal in 33 states, but it remains illegal at the federal level. We discuss the current regulatory landscape, rising support for legalizing cannabis and recent legislative developments.
CNBS invests in marijuana companies that derive 50% or more of their revenue from the cannabis and hemp ecosystem. Its top holdings include Canopy Growth (CGC - Free Report) Aurora Cannabis (ACB - Free Report) , GW Pharmaceuticals MediPharm Labs, Organigram Holdings (OGI - Free Report) Village Farms International (VFF - Free Report) and Canaccord Genuity.
Tim talks about some of his favorite cannabis stocks.
There are four more pot ETFs available to investors now--the ETFMG Alternative Harvest ETF (MJ - Free Report) , the AdvisorShares Pure Cannabis ETF (YOLO - Free Report) , The Cannabis ETF and the Cambria Cannabis ETF (TOKE - Free Report) . How is CNBS different from other pot ETFs?
Are there any pot stocks investors should stay away from? CannTrust Holdings has lost more than 50% of its value since it disclosed a serious regulatory breach on July 8. What else do investors need to know?
Amplify has a number of ETFs focused on disruptive themes, like the Amplify Online Retail ETF (IBUY - Free Report) . We talk about the role of thematic ETFs in investors’ portfolios.
Please visit AmplifyETF.com to learn more about CNBS and other Amplify ETFs.
Make sure to be on the lookout for the next edition of ETF Spotlight! If you have any comments or questions, please email podcast@zacks.com.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>